A randomized, controlled, double-blind phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. Mabthera plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or Mabthe